Cyxone appoints Mangold as market maker

Cyxone AB (publ) announced today that the company has appointed Mangold Fondkommission to provide market making services for the company’s share. The purpose of the market maker is to improve the liquidity of the share and reduce the difference between the buying and selling price. The assignment commences on July 2, 2018.

Mangold will fulfill its assignment as market maker to ensure the possibility of trading in Cyxone’s share every day by continuously placing trading records on each purchase and sales page in the order book. A market maker aims to create a more accurate price picture in a company’s share, which in turn gives a more accurate valuation of the company and allows for an improved trading volume in the share.

Kjell G. Stenberg, CEO of Cyxone, commented, “This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.”

Tags:

About Us

Cyxone AB is a clinical stage biotech company with a portfolio of immunomodulating drugs for the treatment of autoimmune diseases such as multiple sclerosis (MS) and rheumatoid arthritis (RA). The company’s drug portfolio is based on two technological pillars in the form of oral molecules and cyclotide-based drugs that inhibit key processes in the body’s cells that are typically associated with various immune-related disorders. Cyxone’s technologies have the potential to address an unmet need and provide new effective and safe medicines that can improve the quality of life for patients affected by autoimmune diseases. The company has two drug candidates, T20K for MS in clinical phase I program and Rabeximod for RA in clinical phase II program. Cyxone’s Certified Adviser on the Nasdaq First North Growth Market is Mangold Fondkommission AB, +46 (0)8-503 015 50, ca@mangold.se.www.cyxone.com

Subscribe

Documents & Links

Quotes

This market maker is now being implemented to increase liquidity of our stock, which has sometimes been low. We look very favorably on this support measure, which is primarily done to benefit our shareholders through reduced trading risks.
Kjell G. Stenberg, CEO of Cyxone